Neonatal Respiratory Distress Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neonatal Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Neonatal respiratory distress syndrome, or RDS, is a common cause of respiratory distress in a newborn, presenting within hours after birth, most often immediately after delivery. It usually affects preterm neonates and term infants. The incidence of RDS is inversely proportional to the gestational age of the infant, with more severe disease in the smaller and more premature neonates. Treatment modalities include antenatal corticosteroids, surfactants, and advanced respiratory care of the neonate, and though they have improved the outcomes for patients affected by RDS, it continues to be a leading cause of morbidity and mortality in the preterm infant.
The Neonatal Respiratory Distress Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Neonatal Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neonatal Respiratory Distress Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neonatal Respiratory Distress Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neonatal Respiratory Distress Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neonatal Respiratory Distress Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neonatal Respiratory Distress Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AzarGen Biotechnologies (Pty) LtdBill & Melinda Gates Medical Research Institute
BioSuperior Technology Inc
Chiesi Farmaceutici SpA
Molecular Express Inc
VGSK Technologies Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neonatal Respiratory Distress Syndrome reports